CHICAGO, Oct 28 (Reuters) - Discovery Laboratories Inc. (DSCO.O: Quote, Profile, Research) on Friday said its lead drug, Surfaxin, got an orphan drug designation from the U.S. Food and Drug Administration to treat chronic lung disease in premature infants.
